nifedipine has been researched along with Obstructive Lung Diseases in 71 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, a group of 76 consecutive patients with mild-to-moderate hypertension and chronic obstructive pulmonary disease (COPD) were selected to participate in a clinical antihypertensive trial to define the roles of lisinopril, nifedipine and conventional therapy, and their impact on the renin-antiotensin system (RAS)." | 9.08 | Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. ( Chiang, HT; Lee, D; Lin, M; Yang, YF, 1996) |
| "To observe the long-term effect of nifedipine (control release tablets) in patients with chronic obstructive pulmonary disease and cor pulmonale." | 9.08 | [The long-term effect of nifedipine (control release tablets) in patients with chronic obstructive pulmonary disease and cor pulmonale]. ( Cheng, X; Li, Q; Yao, Z, 1997) |
| "The objective of this study was to evaluate the long-term results of an 18 months nifedipine treatment in patients with pulmonary hypertension (PHT) secondary to chronic obstructive broncho-pulmonary disease (COBPD)." | 9.06 | [Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Vestri, R, 1989) |
| "The present study was undertaken to evaluate at rest the short- and long-term effects of oral nifedipine (N) in patients with pulmonary hypertension (PH)." | 7.68 | Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease. ( Domenighetti, GM; Saglini, VG, 1992) |
| "To observe acute hemodynamic effects of pulmonary hypertension in chronic obstructive lung disease by nifedipine, we studied 16 patients with pulsed doppler ultrasound." | 7.68 | [Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease]. ( Yuan, H, 1991) |
| "We evaluated the effects of the calcium channel blocker nifedipine (Nf) as a vasodilator compared with oxygen administration on pulmonary hypertension and right ventricular performance in 15 patients with COPD." | 7.68 | [Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration]. ( Liu, Z; Yu, RJ, 1991) |
| "This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects." | 7.67 | Safety of nifedipine in subjects with bronchial asthma and COPD. ( Bewtra, A; Nair, CK; Nair, N; Townley, RG, 1984) |
| "In 41 patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, the effects of sublingual administration of 20 mg nifedipine and 0." | 7.67 | [Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin]. ( Fridrich, L; Gassner, A; Klicpera, M; Magometschnigg, D; Sommer, G, 1986) |
| "The effects of a single dose of nifedipine (20 mg sublingual) on the haemodynamics and parameters of tissue oxygenation were assessed by right heart catheterisation and oximetry of mixed arterial and venous blood in 24 patients with pulmonary hypertension secondary to severe chronic obstructive airways disease." | 7.67 | [Nifedipine in the treatment of chronic cor pulmonale]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Torresani, J; Tran N'guyen, A, 1986) |
| "The effects of nifedipine on hemodynamics and blood gases were studied in 10 patients with pulmonary hypertension secondary to chronic obstructive lung disease." | 7.67 | Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease. ( Arnaud, A; Guintoli, A; Philip-Joet, F; Saadjian, A; Torresani, J, 1985) |
| "We evaluated in patients suffering from COPD-related pulmonary hypertension whether nifedipine therapy lowers acutely and chronically pulmonary vascular pressure and resistance and whether pulmonary transmural pressure may be further lowered by the combined use of nifedipine and oxygen." | 7.67 | Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. ( Agostoni, P; Doria, E; Galli, C; Guazzi, MD; Tamborini, G, 1989) |
| "In 10 patients with advanced chronic lung disease and pulmonary hypertension central haemodynamics and pulmonary gas exchange were studied at rest and during exercise, before and during continuous infusion of the calcium antagonist felodipine, which lowers vascular resistance by selective action on vascular smooth muscle." | 7.67 | The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease. ( Bratel, T; Hedenstierna, G; Nyquist, O; Ripe, E, 1985) |
| "The effects of a single dose of nifedipine (20 mg sublingually) on hemodynamics and tissue oxygenation were evaluated in 24 patients suffering from pulmonary hypertension secondary to severe chronic obstructive lung disease." | 7.67 | Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A, 1987) |
| "To determine whether Nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance in patients with hypoxic pulmonary hypertension, we have studied ten clinically stable patients with chronic obstructive airways disease following acute administration of sublingual Nifedipine 20 mg and also after three months long term treatment with Nifedipine tablets 20mg bd." | 7.67 | Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. ( Cunnington, AR; Johnson, DC; Joshi, RC; Mehta, R, 1986) |
| "The present study was undertaken to evaluate the short-term effects of nitroglycerin, nifedipine, and supplemental oxygen on hemodynamics and gas exchange in 11 patients in stable condition with chronic obstructive pulmonary disease and cor pulmonale." | 7.67 | Pulmonary vasodilator therapy for chronic obstructive pulmonary disease and cor pulmonale. Treatment with nifedipine, nitroglycerin, and oxygen. ( Belli, A; Giudice, JC; Morley, TF; Zappasodi, SJ, 1987) |
| "The advantages of long-term administration of vasodilators in the treatment of chronic cor pulmonale were investigated after informed consent in 60 patients with obstructive respiratory insufficiency (56 men, 4 women, mean age 63." | 6.66 | One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Surpas, P; Vestri, R, 1988) |
| " Under this aspect we examined 44 patients by right heart catheterisation at rest and at exercise before and after sublingual application of a single dose of 20 mg nifedipine (Corinfar) as well as under continuous dosage of 30-60 mg daily." | 5.28 | The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease. ( Evers, H; Harzbecker, K; Orschekowski, H; Schauer, J; Schilling, W; Steiniger, L; Winkler, J, 1990) |
| " The benefit of long-term administration of nifedipine is difficult to predict on the basis of short-term effects." | 5.27 | Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD). ( Bassein, L; Gunella, G; Schiavina, M; Sturani, C, 1983) |
| " Thus, a group of 76 consecutive patients with mild-to-moderate hypertension and chronic obstructive pulmonary disease (COPD) were selected to participate in a clinical antihypertensive trial to define the roles of lisinopril, nifedipine and conventional therapy, and their impact on the renin-antiotensin system (RAS)." | 5.08 | Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. ( Chiang, HT; Lee, D; Lin, M; Yang, YF, 1996) |
| "To observe the long-term effect of nifedipine (control release tablets) in patients with chronic obstructive pulmonary disease and cor pulmonale." | 5.08 | [The long-term effect of nifedipine (control release tablets) in patients with chronic obstructive pulmonary disease and cor pulmonale]. ( Cheng, X; Li, Q; Yao, Z, 1997) |
| "To assess changes in physiologic shunting and oxygenation following short-term treatment with nifedipine in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease." | 5.07 | Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. ( Bone, MF; Kalra, L, 1993) |
| "The objective of this study was to evaluate the long-term results of an 18 months nifedipine treatment in patients with pulmonary hypertension (PHT) secondary to chronic obstructive broncho-pulmonary disease (COBPD)." | 5.06 | [Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Vestri, R, 1989) |
| " Biochemical evidence suggests that pulmonary vasoconstriction results from the transmembrane flux of calcium into vascular smooth muscle; accordingly, the pulmonary pressor responses in experimental hypoxic pulmonary hypertension can be attenuated by verapamil and nifedipine." | 4.77 | Therapeutic application of calcium-channel antagonists for pulmonary hypertension. ( Packer, M, 1985) |
| "We evaluated the effects of the calcium channel blocker nifedipine (Nf) as a vasodilator compared with oxygen administration on pulmonary hypertension and right ventricular performance in 15 patients with COPD." | 3.68 | [Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration]. ( Liu, Z; Yu, RJ, 1991) |
| "The hydraulic load of the right and left ventricles and the clinical effects of nifedipine were evaluated in 8 normal subjects (mean age: 55 years) and 8 patients with cor pulmonale secondary to chronic obstructive lung disease (mean age: 57 years)." | 3.68 | Aortic and pulmonary input impedance in patients with cor pulmonale. ( Chang, MK; Chen, JS; Chen, KS; Chen, YT; Chiang, BN; Hu, WH; Lee, DY; Lee, YS; Lin, JR; Lin, WW, 1990) |
| "To observe acute hemodynamic effects of pulmonary hypertension in chronic obstructive lung disease by nifedipine, we studied 16 patients with pulsed doppler ultrasound." | 3.68 | [Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease]. ( Yuan, H, 1991) |
| "The present study was undertaken to evaluate at rest the short- and long-term effects of oral nifedipine (N) in patients with pulmonary hypertension (PH)." | 3.68 | Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease. ( Domenighetti, GM; Saglini, VG, 1992) |
| "Non-invasive measurements of right and left ventricular ejection fraction (RVEF, LVEF) by multiple-gated equilibrium radionuclide ventriculography were performed in 19 control subjects, 55 patients with COPD and cor pulmonale, simultaneous right heart catheterizations were performed in 10 patients with cor pulmonale to determine the mean pulmonary artery pressure (mPAP), and then, the acute hemodynamic and functional effects of nifedipine were evaluated." | 3.68 | [Measurement of right and left heart function of COPD and cor pulmonale by radionuclide ventriculography]. ( Wu, WQ, 1992) |
| "This prospective study was undertaken to evaluate the safety of nifedipine, a calcium channel blocking agent, on 60 subjects with asthma, chronic obstructive pulmonary disease (COPD), angina, and normal subjects." | 3.67 | Safety of nifedipine in subjects with bronchial asthma and COPD. ( Bewtra, A; Nair, CK; Nair, N; Townley, RG, 1984) |
| "To determine whether nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance index during rest and exercise in patients with hypoxic pulmonary hypertension, we studied 6 clinically stable patients using a randomized, double-blind, crossover design." | 3.67 | Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study. ( Huang, CK; Kallman, CH; Kennedy, TP; Michael, JR; Schlott, W; Summer, W; Zahka, K, 1984) |
| "We studied the simultaneous effects of nifedipine on the pulmonary circulation and blood gases in 12 patients with pulmonary hypertension secondary to obstructive chronic bronchitis." | 3.67 | [Value of nifedipine in respiratory failure related to obstructive chronic bronchitis during treatment over 6 months]. ( Boita, F; Boutaud, P; Herpin, D; Ingrand, P; Meurice, JC; Patte, F; Underner, M, 1989) |
| "We evaluated in patients suffering from COPD-related pulmonary hypertension whether nifedipine therapy lowers acutely and chronically pulmonary vascular pressure and resistance and whether pulmonary transmural pressure may be further lowered by the combined use of nifedipine and oxygen." | 3.67 | Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. ( Agostoni, P; Doria, E; Galli, C; Guazzi, MD; Tamborini, G, 1989) |
| "The effects of a single dose of nifedipine (20 mg sublingual) on the haemodynamics and parameters of tissue oxygenation were assessed by right heart catheterisation and oximetry of mixed arterial and venous blood in 24 patients with pulmonary hypertension secondary to severe chronic obstructive airways disease." | 3.67 | [Nifedipine in the treatment of chronic cor pulmonale]. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Torresani, J; Tran N'guyen, A, 1986) |
| "In 41 patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, the effects of sublingual administration of 20 mg nifedipine and 0." | 3.67 | [Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin]. ( Fridrich, L; Gassner, A; Klicpera, M; Magometschnigg, D; Sommer, G, 1986) |
| "The present study was undertaken to evaluate the short-term effects of nitroglycerin, nifedipine, and supplemental oxygen on hemodynamics and gas exchange in 11 patients in stable condition with chronic obstructive pulmonary disease and cor pulmonale." | 3.67 | Pulmonary vasodilator therapy for chronic obstructive pulmonary disease and cor pulmonale. Treatment with nifedipine, nitroglycerin, and oxygen. ( Belli, A; Giudice, JC; Morley, TF; Zappasodi, SJ, 1987) |
| "To determine whether Nifedipine reduces pulmonary artery pressure and pulmonary vascular resistance in patients with hypoxic pulmonary hypertension, we have studied ten clinically stable patients with chronic obstructive airways disease following acute administration of sublingual Nifedipine 20 mg and also after three months long term treatment with Nifedipine tablets 20mg bd." | 3.67 | Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. ( Cunnington, AR; Johnson, DC; Joshi, RC; Mehta, R, 1986) |
| "The effects of a single dose of nifedipine (20 mg sublingually) on hemodynamics and tissue oxygenation were evaluated in 24 patients suffering from pulmonary hypertension secondary to severe chronic obstructive lung disease." | 3.67 | Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A, 1987) |
| "We used an improved noninvasive radionuclide method, recently developed by us, to evaluate changes in pulmonary artery pressure induced by sublingual nifedipine in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 3.67 | The value of right atrial emptying rate in predicting reduction in pulmonary artery pressure in patients with chronic obstructive pulmonary disease. ( Frankel, A; Marmor, AT; Michaeli, S; Plich, M; Schneeweiss, A, 1987) |
| "The effects of nifedipine on hemodynamics and blood gases were studied in 10 patients with pulmonary hypertension secondary to chronic obstructive lung disease." | 3.67 | Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease. ( Arnaud, A; Guintoli, A; Philip-Joet, F; Saadjian, A; Torresani, J, 1985) |
| "In 10 patients with advanced chronic lung disease and pulmonary hypertension central haemodynamics and pulmonary gas exchange were studied at rest and during exercise, before and during continuous infusion of the calcium antagonist felodipine, which lowers vascular resistance by selective action on vascular smooth muscle." | 3.67 | The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease. ( Bratel, T; Hedenstierna, G; Nyquist, O; Ripe, E, 1985) |
| "Almitrine infusion was followed by an increase in PaO2 (20%) and PVR (48%)." | 2.67 | Nifedipine inhibits the effects of almitrine in patients suffering from pulmonary artery hypertension secondary to chronic obstructive pulmonary disease. ( Arnaud, A; Barret, A; Levy, S; Philip-Joët, F; Saadjian, A, 1993) |
| "The advantages of long-term administration of vasodilators in the treatment of chronic cor pulmonale were investigated after informed consent in 60 patients with obstructive respiratory insufficiency (56 men, 4 women, mean age 63." | 2.66 | One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease. ( Arnaud, A; Philip-Joet, F; Saadjian, A; Surpas, P; Vestri, R, 1988) |
| "This long-term controlled study was undertaken to assess the haemodynamic effects of chronic administration of Nifedipine (N)." | 2.66 | Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. ( Arnaud, AG; Philip-Joet, FF; Saadjian, AY; Vestri, R, 1988) |
| "Pretreatment with nifedipine significantly attenuated the hypoxia-induced increase in mean pulmonary artery pressure by 53% and of the mean pulmonary vascular resistance index by 50%." | 2.66 | Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease. ( Burghuber, OC, 1987) |
| " Under this aspect we examined 44 patients by right heart catheterisation at rest and at exercise before and after sublingual application of a single dose of 20 mg nifedipine (Corinfar) as well as under continuous dosage of 30-60 mg daily." | 1.28 | The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease. ( Evers, H; Harzbecker, K; Orschekowski, H; Schauer, J; Schilling, W; Steiniger, L; Winkler, J, 1990) |
| " The benefit of long-term administration of nifedipine is difficult to predict on the basis of short-term effects." | 1.27 | Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD). ( Bassein, L; Gunella, G; Schiavina, M; Sturani, C, 1983) |
| "Nifedipine was given, 20 mg sublingually, to 6 patients with pulmonary hypertension secondary to advanced chronic obstructive pulmonary disease, and its effects on hemodynamics, blood gases, lung mechanics, and the distribution of ventilation-perfusion ratios (VA/Q) were investigated." | 1.27 | Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. ( Hallemans, R; Lejeune, P; Melot, C; Mols, P; Naeije, R, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (69.01) | 18.7374 |
| 1990's | 22 (30.99) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Melot, C | 1 |
| Hallemans, R | 1 |
| Naeije, R | 1 |
| Mols, P | 2 |
| Lejeune, P | 1 |
| Feret, J | 1 |
| Bruet, A | 1 |
| Simon, N | 1 |
| Duruy, D | 1 |
| Nouailhat, F | 1 |
| Havel, V | 1 |
| Král, B | 2 |
| Eliás, J | 1 |
| Hamet, A | 2 |
| Cernohorský, D | 2 |
| Watanabe, S | 2 |
| Nair, N | 1 |
| Townley, RG | 1 |
| Bewtra, A | 1 |
| Nair, CK | 1 |
| Kennedy, TP | 2 |
| Michael, JR | 2 |
| Huang, CK | 1 |
| Kallman, CH | 1 |
| Zahka, K | 1 |
| Schlott, W | 1 |
| Summer, W | 1 |
| Sturani, C | 1 |
| Bassein, L | 1 |
| Schiavina, M | 1 |
| Gunella, G | 1 |
| Fanta, CH | 1 |
| Venugopalan, CS | 1 |
| Lacouture, PG | 1 |
| Drazen, JM | 1 |
| Saadjian, A | 8 |
| Philip-Joët, F | 6 |
| Barret, A | 1 |
| Levy, S | 1 |
| Arnaud, A | 8 |
| Wu, WQ | 2 |
| Rong, ZS | 1 |
| Yang, XQ | 1 |
| Grewal, KS | 1 |
| Schwartz, HR | 1 |
| Krichbaum, D | 1 |
| Kalra, L | 2 |
| Bone, MF | 2 |
| Huynh, CH | 1 |
| Dechamps, P | 1 |
| Naeije, N | 1 |
| Ham, HR | 1 |
| Lin, M | 1 |
| Yang, YF | 1 |
| Lee, D | 1 |
| Chiang, HT | 1 |
| Cheng, X | 1 |
| Yao, Z | 1 |
| Li, Q | 1 |
| Bonaduce, D | 1 |
| Ferrara, N | 1 |
| Postiglione, M | 1 |
| Petretta, M | 1 |
| Covelli, A | 1 |
| Romano, E | 1 |
| Rengo, F | 1 |
| Xu, JY | 1 |
| Li, BX | 1 |
| Cheng, SY | 1 |
| Domenighetti, GM | 1 |
| Saglini, VG | 1 |
| Dujić, Z | 1 |
| Tocilj, J | 1 |
| Slavković, V | 1 |
| Frank-Piskorska, A | 1 |
| Wnuk, J | 1 |
| Kozak, E | 1 |
| Yuan, H | 1 |
| Liu, Z | 1 |
| Yu, RJ | 1 |
| Torbicki, A | 1 |
| Tramarin, R | 1 |
| Fracchia, C | 1 |
| Mortara, A | 1 |
| Ambrosino, N | 1 |
| Pozzoli, M | 1 |
| Rampulla, C | 1 |
| Cobelli, F | 1 |
| Schauer, J | 2 |
| Orschekowski, H | 2 |
| Steiniger, L | 1 |
| Winkler, J | 1 |
| Schilling, W | 1 |
| Harzbecker, K | 1 |
| Evers, H | 1 |
| Kaspar, P | 1 |
| Härtl, W | 1 |
| Petro, W | 1 |
| Gassner, A | 2 |
| Sommer, G | 2 |
| Fridrich, L | 2 |
| Magometschnigg, D | 2 |
| Priol, A | 1 |
| Chen, YT | 1 |
| Chen, KS | 1 |
| Chen, JS | 1 |
| Lin, WW | 1 |
| Hu, WH | 1 |
| Chang, MK | 1 |
| Lee, DY | 1 |
| Lee, YS | 1 |
| Lin, JR | 1 |
| Chiang, BN | 1 |
| Mikunis, RI | 1 |
| Demidiuk, VT | 1 |
| Agustí, AG | 1 |
| Barberá, JA | 1 |
| Roca, J | 1 |
| Wagner, PD | 1 |
| Guitart, R | 1 |
| Rodriguez-Roisín, R | 1 |
| Luther, R | 1 |
| Wichert, H | 1 |
| Köhler, E | 1 |
| Banditt, P | 1 |
| Walther, H | 1 |
| Ahmed, T | 1 |
| Abraham, WM | 1 |
| Berman, BA | 1 |
| Ross, RN | 1 |
| Himmel, W | 1 |
| Paleev, NR | 1 |
| Tsa'rkova, LN | 1 |
| Uribe-Echevarria, EE | 1 |
| Baklykova, SN | 1 |
| Novoderezhkina, LB | 1 |
| Turetta, F | 1 |
| De Stefani, R | 1 |
| Milanesi, A | 1 |
| Cannizzaro, A | 1 |
| Stievano, N | 1 |
| Bossi, A | 1 |
| Simone, M | 1 |
| Meurice, JC | 1 |
| Boutaud, P | 1 |
| Herpin, D | 1 |
| Ingrand, P | 1 |
| Boita, F | 1 |
| Underner, M | 1 |
| Patte, F | 1 |
| Vestri, R | 5 |
| Agostoni, P | 2 |
| Doria, E | 2 |
| Galli, C | 2 |
| Tamborini, G | 2 |
| Guazzi, MD | 1 |
| Philip-Joft, F | 1 |
| Lagier, F | 1 |
| Joet, FP | 1 |
| Surpas, P | 1 |
| Saadjian, AY | 1 |
| Philip-Joet, FF | 1 |
| Arnaud, AG | 1 |
| Tran N'guyen, A | 1 |
| Torresani, J | 2 |
| Klicpera, M | 1 |
| Morley, TF | 1 |
| Zappasodi, SJ | 1 |
| Belli, A | 1 |
| Giudice, JC | 1 |
| Corriveau, ML | 1 |
| Rosen, BJ | 1 |
| Keller, CA | 1 |
| Chun, DS | 1 |
| Dolan, GF | 1 |
| Mohsenifar, Z | 1 |
| Jasper, AC | 1 |
| Koerner, SK | 1 |
| Fiorentini, C | 1 |
| Guazzi, M | 1 |
| Ariaraj, SJ | 1 |
| Alkrishna, B | 1 |
| Gupta, HL | 1 |
| Girdhar, KK | 1 |
| Mittal, A | 1 |
| Johnson, DC | 1 |
| Joshi, RC | 1 |
| Mehta, R | 1 |
| Cunnington, AR | 1 |
| Raimondi, GA | 1 |
| Raimondi, AC | 1 |
| Dzienisik, RS | 1 |
| Borrajo, MC | 1 |
| González, SB | 1 |
| Marmor, AT | 1 |
| Michaeli, S | 1 |
| Plich, M | 1 |
| Frankel, A | 1 |
| Schneeweiss, A | 1 |
| Burghuber, OC | 1 |
| Bratel, T | 2 |
| Hedenstierna, G | 2 |
| Nyquist, O | 2 |
| Ripe, E | 2 |
| Handa, S | 1 |
| Fujii, I | 1 |
| Ohonishi, S | 1 |
| Yamazaki, H | 1 |
| Nakamura, Y | 1 |
| Tatsumi, K | 1 |
| Kuriyama, T | 1 |
| Saito, M | 1 |
| Kimura, H | 1 |
| Okada, O | 1 |
| Kunitomo, F | 1 |
| Tojima, H | 1 |
| Okita, S | 1 |
| Yuguchi, Y | 1 |
| Rolla, G | 1 |
| Arossa, W | 1 |
| Bucca, C | 1 |
| Bugiani, M | 1 |
| Packer, M | 1 |
| Santos Bouza, AA | 1 |
| López Pérez, JM | 1 |
| Ikeda, H | 1 |
| Takahashi, K | 1 |
| Sasaki, H | 1 |
| Ito, E | 1 |
| Yasui, S | 1 |
| Selinger, S | 1 |
| Parham, W | 1 |
| Buescher, P | 1 |
| Wong, D | 1 |
| Muramoto, A | 1 |
| Caldwell, J | 1 |
| Albert, RK | 1 |
| Lakshminarayan, S | 1 |
| Butler, J | 1 |
| Domenighetti, G | 1 |
| Guintoli, A | 1 |
5 reviews available for nifedipine and Obstructive Lung Diseases
| Article | Year |
|---|---|
[New therapeutic agents and hypoxic pulmonary vasoconstriction].
Topics: Aminophylline; Anesthetics; Bronchodilator Agents; Humans; Hypoxia; Lung; Lung Diseases, Obstructive | 1983 |
Role of calcium-channel blockers in obstructive airway disease.
Topics: Acetylcholine; Animals; Asthma; Asthma, Exercise-Induced; Calcium; Calcium Channel Blockers; Diltiaz | 1985 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Ca | 1986 |
[Effects of nifedipine in patients with chronic obstructive bronchitis and pulmonary hypertension undergoing artificial respiration].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine; Oxygen; Respi | 1989 |
Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
Topics: Animals; Calcium Channel Blockers; Cattle; Diltiazem; Hemodynamics; Humans; Hypertension, Pulmonary; | 1985 |
15 trials available for nifedipine and Obstructive Lung Diseases
| Article | Year |
|---|---|
Nifedipine inhibits the effects of almitrine in patients suffering from pulmonary artery hypertension secondary to chronic obstructive pulmonary disease.
Topics: Almitrine; Blood Gas Analysis; Cardiac Catheterization; Double-Blind Method; Female; Hemodynamics; H | 1993 |
Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease.
Topics: Administration, Sublingual; Blood Gas Analysis; Blood Pressure; Catheterization, Swan-Ganz; Female; | 1993 |
Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Female; Humans; Hypertensi | 1996 |
[The long-term effect of nifedipine (control release tablets) in patients with chronic obstructive pulmonary disease and cor pulmonale].
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind | 1997 |
Effects of nifedipine on diffusing capacity and pulmonary capillary blood volume in chronic obstructive pulmonary disease. A controlled study.
Topics: Adult; Aged; Blood Volume; Double-Blind Method; Humans; Lung Diseases, Obstructive; Male; Middle Age | 1991 |
[Evaluation of a single oral dose of nifedipine on the right- ventricular ejection fraction in patients with chronic obstructive lung diseases].
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Female; Humans; Lung Diseases, Obstruc | 1991 |
[Modification of pulmonary hypertension in patients with chronic obstructive lung diseases using calcium antagonists in an acute trial].
Topics: Administration, Sublingual; Adult; Aged; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; | 1989 |
[Nifedipine treatment of pulmonary hypertension as a complication of chronic obstructive diseases of the lungs].
Topics: Adult; Anti-Arrhythmia Agents; Clinical Trials as Topic; Female; Hemodynamics; Humans; Hypertension, | 1989 |
[Long-term treatment of pulmonary hypertension in chronic obstructive bronchopneumopathies with nifedipine. Hemodynamic study over 18 months].
Topics: Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive | 1989 |
[Long-term clinical study of nifedipine in the treatment of pulmonary arterial hypertension in chronic obstructive bronchopneumopathies].
Topics: Clinical Trials as Topic; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; | 1987 |
[Hemodynamic effects of the administration of nifedipine over an 18-month period in pulmonary arterial hypertension in chronic obstructive bronchopneumopathies].
Topics: Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine | 1988 |
One-year clinical study on nifedipine in the treatment of pulmonary hypertension in chronic obstructive lung disease.
Topics: Aged; Clinical Trials as Topic; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obs | 1988 |
Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study.
Topics: Clinical Trials as Topic; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obst | 1988 |
Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease.
Topics: Aged; Cardiac Output; Female; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Mid | 1987 |
Effect of nifedipine on salbutamol-induced bronchodilation in partially reversible airway obstruction.
Topics: Adult; Aged; Airway Resistance; Albuterol; Double-Blind Method; Drug Interactions; Forced Expiratory | 1986 |
51 other studies available for nifedipine and Obstructive Lung Diseases
| Article | Year |
|---|---|
Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease.
Topics: Aged; Arteries; Biomechanical Phenomena; Female; Hemodynamics; Humans; Lung; Lung Diseases, Obstruct | 1984 |
[Chronic obstructive bronchopneumopathies. Effect of nifedipine during the exercise test].
Topics: Adult; Aged; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Ob | 1983 |
[Spiroergometry in patients with hypoxic pulmonary hypertension treated with Corinfar].
Topics: Adult; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Nifedipine; O | 1984 |
Safety of nifedipine in subjects with bronchial asthma and COPD.
Topics: Adult; Aged; Angina Pectoris; Asthma; Female; Forced Expiratory Flow Rates; Forced Expiratory Volume | 1984 |
Calcium channel blocking agents. Council on scientific affairs.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Asthma; Calcium Channel Blockers; Cardiomyopathy, Hy | 1983 |
Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease. A controlled double-blind study.
Topics: Aged; Double-Blind Method; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive | 1984 |
Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD).
Topics: Administration, Oral; Aged; Hemodynamics; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Nif | 1983 |
Inhibition of bronchoconstriction in the guinea pig by a calcium channel blocker, nifedipine.
Topics: Animals; Bronchi; Carbachol; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; In Vitro Tech | 1982 |
Hydralazine in pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine | 1982 |
[Hemodynamic studies of pulmonary heart diseases and the effects of nifedipine].
Topics: Aged; Blood Gas Analysis; Catheterization, Swan-Ganz; Echocardiography; Female; Hemodynamics; Humans | 1994 |
Nifedipine and acute renal failure.
Topics: Acute Kidney Injury; Aged; Humans; Hypertension; Lung Diseases, Obstructive; Male; Nifedipine | 1993 |
Acute effects of nifedipine on systolic and diastolic ventricular function in patients with chronic obstructive pulmonary disease.
Topics: Administration, Sublingual; Aged; Gated Blood-Pool Imaging; Hemodynamics; Humans; Lung Diseases, Obs | 1993 |
[Effects of the administration of Ca++ antagonist on bronchial resistance in subjects with chronic obstructive bronchopneumopathy].
Topics: Adult; Airway Resistance; Calcium; Chronic Disease; Female; Humans; Lung Diseases, Obstructive; Male | 1978 |
[Short-term effects of Angelica sinensis and nifedipine on chronic obstructive pulmonary disease in patients with pulmonary hypertension].
Topics: Aged; Cardiac Output; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hemodynamics; Humans | 1992 |
[Measurement of right and left heart function of COPD and cor pulmonale by radionuclide ventriculography].
Topics: Blood Pressure; Female; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Nifedipine; Pulmonary | 1992 |
Short- and long-term hemodynamic effects of oral nifedipine in patients with pulmonary hypertension secondary to COPD and lung fibrosis. Deleterious effects in patients with restrictive disease.
Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middl | 1992 |
[Pulsed Doppler echocardiography assessment of acute hemodynamic effects of nifedipine on pulmonary hypertension in chronic obstructive lung disease].
Topics: Administration, Sublingual; Adult; Aged; Blood Pressure; Echocardiography, Doppler; Female; Hemodyna | 1991 |
[Effects of nifedipine on pulmonary hypertension in patients with chronic obstructive pulmonary diseases--a comparison with oxygen administration].
Topics: Administration, Sublingual; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Ob | 1991 |
Simultaneous Doppler and thermodilution assessment of pulmonary artery flow during acute interventions in patients with chronic obstructive pulmonary disease.
Topics: Administration, Sublingual; Blood Flow Velocity; Carbon Dioxide; Echocardiography, Doppler; Exercise | 1990 |
The influence of nifedipine (Corinfar) on pulmonary hypertension in chronic obstructive lung disease.
Topics: Adolescent; Adult; Aged; Female; Humans; Hypertension, Pulmonary; Long-Term Care; Lung Diseases, Obs | 1990 |
[Effect of nifedipine alone and in combination with salbutamol on the beat frequency of human nasal cilia].
Topics: Albuterol; Dose-Response Relationship, Drug; Drug Interactions; Humans; Lung Diseases, Obstructive; | 1990 |
Differential therapy with calcium antagonists in pulmonary hypertension secondary to COPD. Hemodynamic effects of nifedipine, diltiazem, and verapamil.
Topics: Calcium Channel Blockers; Diltiazem; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; L | 1990 |
Aortic and pulmonary input impedance in patients with cor pulmonale.
Topics: Aorta; Blood Pressure; Humans; Lung Diseases, Obstructive; Middle Aged; Nifedipine; Pulmonary Artery | 1990 |
[Foridon in the combined treatment of patients with chronic obstructive lung diseases].
Topics: Adolescent; Adult; Blood Pressure; Bronchi; Calcium Channel Blockers; Drug Evaluation; Female; Human | 1990 |
Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease.
Topics: Exercise; Exercise Test; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Nifedipine; Pulmonar | 1990 |
[Interactions of theophylline and nifedipine].
Topics: Adult; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hy | 1990 |
[Value of nifedipine in respiratory failure related to obstructive chronic bronchitis during treatment over 6 months].
Topics: Administration, Sublingual; Drug Administration Schedule; Hemodynamics; Humans; Hypertension, Pulmon | 1989 |
Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Exercise Test; Female; Humans; Hypertension, Pulmonary; | 1989 |
Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension.
Topics: Adult; Carbon Dioxide; Cardiac Output; Female; Heart Rate; Humans; Hypertension, Pulmonary; Hypoxia; | 1985 |
[Nifedipine in the treatment of chronic cor pulmonale].
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lactates; Lung Diseases, Obstruc | 1986 |
[Vasodilator therapy in pulmonary hypertension and chronic obstructive lung disease (COPD). Hemodynamic studies exemplified by nifedipine and nitroglycerin].
Topics: Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Long-Term Care; Lung Diseases, Obstruc | 1986 |
Pulmonary vasodilator therapy for chronic obstructive pulmonary disease and cor pulmonale. Treatment with nifedipine, nitroglycerin, and oxygen.
Topics: Administration, Oral; Carbon Dioxide; Drug Evaluation; Female; Hemodynamics; Humans; Injections, Int | 1987 |
Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease.
Topics: Carbon Dioxide; Carbon Monoxide; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Di | 1988 |
Relationship between oxygen uptake and oxygen delivery in patients with pulmonary hypertension.
Topics: Biological Availability; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension, Pulmonary; Lu | 1988 |
[Hypoxic pulmonary hypertension: nifedipine therapy].
Topics: Aged; Drug Evaluation; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruc | 1988 |
Nifedipine-aminophylline interaction.
Topics: Aged; Aminophylline; Drug Interactions; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Nifed | 1988 |
Effect of nifedipine in chronic obstructive airways disease.
Topics: Adult; Female; Humans; Lung Diseases, Obstructive; Middle Aged; Nifedipine; Respiratory Function Tes | 1988 |
Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease.
Topics: Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middl | 1986 |
Lack of effect of nifedipine and pulmonary hypertension in a group of COPD decompensated patients.
Topics: Hemodynamics; Humans; Lung Diseases, Obstructive; Nifedipine; Oxygen; Pulmonary Gas Exchange; Pulmon | 1986 |
Hemodynamic and oxygen delivery responses to nifedipine in pulmonary hypertension secondary to chronic obstructive lung disease.
Topics: Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male | 1987 |
The value of right atrial emptying rate in predicting reduction in pulmonary artery pressure in patients with chronic obstructive pulmonary disease.
Topics: Blood Pressure; Female; Heart; Heart Atria; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruct | 1987 |
Long-term treatment with a new calcium antagonist, felodipine, in chronic obstructive lung disease.
Topics: Calcium Channel Blockers; Dose-Response Relationship, Drug; Exercise Test; Felodipine; Humans; Hyper | 1986 |
Strategy to manage pump failure due to chronic pulmonary diseases--pathophysiology and treatment of right ventricular overload.
Topics: Alprostadil; Echocardiography; Heart; Heart Diseases; Heart Ventricles; Humans; Hypertension, Pulmon | 1986 |
[Effects of nifedipine on gas exchange in patients with chronic lung disease].
Topics: Lung Diseases, Obstructive; Nifedipine; Pulmonary Gas Exchange | 1986 |
[Immediate effects of nifedipine and oxygen in acute episodes of chronic cor pulmonale].
Topics: Adult; Aged; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Middle Aged; Nifedipine; O | 1985 |
Acute effects of nifedipine on patients with chronic obstructive lung disease.
Topics: Adult; Aged; Airway Resistance; Asthma; Blood Gas Analysis; Blood Pressure; Female; Forced Expirator | 1985 |
Use of calcium channel blockers in hypoxic lung disease.
Topics: Calcium Channel Blockers; Humans; Hypoxia; Lung Diseases; Lung Diseases, Obstructive; Nifedipine; Ox | 1985 |
Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension, Pulmonary; Hypotension; Lung Diseases, Obstruct | 1985 |
[Variable hemodynamic response to nifedipine in pulmonary hypertension secondary to chronic obstructive bronchopathy and pulmonary fibrosis].
Topics: Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases | 1985 |
The effect of a new calcium antagonist, felodipine, on pulmonary hypertension and gas exchange in chronic obstructive lung disease.
Topics: Adult; Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Felodipine; Female; Hemodyn | 1985 |
Two-week nifedipine treatment for pulmonary hypertension complicating chronic obstructive lung disease.
Topics: Administration, Oral; Aged; Cardiac Output; Humans; Hypertension, Pulmonary; Lung Diseases, Obstruct | 1985 |